Generic Name and Formulations:
Nicotine 7mg/24hr, 14mg/24hr, 21mg/24hr; transdermal patch.
Dr. Reddy's Laboratories, Inc.
Indications for HABITROL:
Adjunct in smoking cessation therapy.
≥18yrs: Apply to clean, dry, nonhairy site on trunk or upper outer arm; rotate application site. Remove patch after 24 hours; if vivid dreams or other sleep disturbances occur, remove at bedtime and reapply in AM. >10cigarettes/day: initially one 21mg patch daily for 4 weeks; then one 14mg patch daily for 2 weeks, then one 7mg patch daily for 2 weeks, then stop. ≤10cigarettes/day: initially one 14mg patch daily for 6 weeks then one 7mg patch daily for 2 weeks, then stop. Max 1 patch/24hrs. Do not cut patch.
<18yrs: not recommended.
Concurrent smoking or use of other nicotine products.
Discontinue if irregular heartbeat, palpitations, allergic reaction, or symptoms of nicotine overdose occur. Heart disease. Post-MI. Arrhythmias. Hypertension. Depression. Asthma. Allergy to adhesive tape, other skin problems. Stomach ulcers. Diabetes. History of seizures. Low doses may be toxic to children and pets; discard properly. Pregnancy: not recommended. Nursing mothers.
Remove patch prior to MRI procedures. Smoking cessation potentiates theophylline, insulin, β-blockers, pentazocine, oxazepam, tricyclic antidepressants (eg, imipramine), caffeine, acetaminophen, adrenergic antagonists (eg, prazosin, labetalol), others. Smoking cessation antagonizes adrenergic agonists (eg, isoproterenol, phenylephrine), others.
Local irritation, GI upset, headache, dizziness, palpitations, hypertension.
Patch 7mg, 14mg—7, 14; 21mg—7, 14, 28
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness